The industry of nonsteroidal androgens,and particularly selective androgen receptor modulators (SARMs), has grown tremendously because the first report in 1998. Many of the major pharmaceutical companies have recently published in vivo characterizations of tissue selective AR agonists, as well as rate of latest contributionsto our field carries on accelerate. The increase of the field has triggered a broadening from the chemical space originally occupied via the traditional ster...